Literature DB >> 23963484

Letter regarding "Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts".

Hamid Namazi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23963484      PMCID： PMC3804694          DOI： 10.1007/s00586-013-2951-x

Source DB:  PubMed          Journal:  Eur Spine J        ISSN： 0940-6719            Impact factor:   3.134


× No keyword cloud information.
  4 in total

1.  Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.

Authors:  Davide Gatti; Ombretta Viapiana; Elena Fracassi; Luca Idolazzi; Carmela Dartizio; Maria Rosaria Povino; Silvano Adami; Maurizio Rossini
Journal:  J Bone Miner Res       Date:  2012-11       Impact factor: 6.741

2.  Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts.

Authors:  Tobias Lange; Christoph Stehling; Birgit Fröhlich; Mark Klingenhöfer; Philip Kunkel; Reinhard Schneppenheim; Gabriele Escherich; Georg Gosheger; Jendrik Hardes; Heribert Jürgens; Tobias L Schulte
Journal:  Eur Spine J       Date:  2013-03-01       Impact factor: 3.134

3.  Rspo 1 promotes osteoblast differentiation via Wnt signaling pathway.

Authors:  Ashish R Sharma; Byung-Soo Choi; Jong-Min Park; Dong-Hyun Lee; Jeong-Eun Lee; Hae-Sung Kim; Jeong-Kyo Yoon; Dong-Keun Song; Ju-Suk Nam; Sang-Soo Lee
Journal:  Indian J Biochem Biophys       Date:  2013-02       Impact factor: 1.918

Review 4.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458
  4 in total
  1 in total

Review 1.  The Michel Benoist and Robert Mulholland Yearly European Spine Journal Review: a survey of the "medical" articles in the European Spine Journal, 2013.

Authors:  Michel Benoist
Journal:  Eur Spine J       Date:  2013-12-13       Impact factor: 3.134
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.